{
  "ticker": "OPL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974511",
  "id": "02974511",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250730",
  "time": "1234",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9vw32tl513m.pdf",
  "summary": "**Material Information Summary (ASX: OPL) \u2013 Quarterly Report (Appendix 4C)**  \n\n- **Commercial Highlights**:  \n  - Secured three key deals:  \n    - **Innovatrix Capital** partnership (parametric insurance, retainer + premium-share revenue).  \n    - Pilot engagements with **CROs Cardialysis** (cardiovascular) and **Evestia** (oncology/rare disease).  \n  - Strategic focus on accelerating AI capabilities and data expansion (520k trials / 780M datapoints).  \n  - New Chief Revenue Officer (**Matt Hallam**) appointed to drive sales.  \n\n- **Capital & Treasury**:  \n  - **$1.5M placement** (oversubscribed, Tranche 2 pending).  \n  - **2 Bitcoin held** (~A$331k via BTX ETF; 160% annualized return as of 28 July).  \n  - **$2M standby loan facility** from director Tony G.  \n\n- **Financial Position**:  \n  - **Cash balance**: **$102k** (up from $64k last quarter).  \n  - **Operating cash outflow**: **$390k** (up $128k QoQ).  \n  - **Government grants/tax incentives**: **$293k** received.  \n\n- **Near-Term Catalysts**:  \n  - Convert pilot deals (Innovatrix, Cardialysis, Evestia) to recurring revenue.  \n  - Pursue M&A/data partnerships.  \n  - Showcase AI platform at **BIO Korea/Boston**.  \n\n- **Corporate Action**:  \n  - Pending **name change** to *Pathkey.AI Limited* (ticker: **PKY**).  \n\n*Omit: Routine operational details, director fees, non-material expenditures.*",
  "usage": {
    "prompt_tokens": 4785,
    "completion_tokens": 370,
    "total_tokens": 5155,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T03:33:03.846355"
}